Ai Iwauchi, Nei Fukasawa, Jun Takei, Miku Maeda, Kyoichi Tomoto, Akihiko Teshigawara, Yohei Yamamoto, Yasuharu Akasaki, Yuzuru Hasegawa, Yuichi Murayama, et al. Comparative analyses of erythroblast transformation specific-1 related gene expression before and after neoadjuvant bevacizumab therapy for newly diagnosed glioblastoma. Int J Clin Exp Pathol. 2024. 17. 10. 346-359
Rintaro Tachi, Michiyasu Fuga, Toshihide Tanaka, Akihiko Teshigawara, Ikki Kajiwara, Koreaki Irie, Toshihiro Ishibashi, Yuzuru Hasegawa, Yuichi Murayama. The white-collar sign after Neuroform Atlas stent-assisted coil embolization of unruptured intracranial aneurysms. The Neuroradiology Journal. 2024
Taketo Ezaki, Toshihide Tanaka, Ryota Tamura, Kentaro Ohara, Yohei Yamamoto, Jun Takei, Yukina Morimoto, Ryotaro Imai, Yuki Kuranari, Yasuharu Akasaki, et al. Correction: Status of alternative angiogenic pathways in glioblastoma resected under and after bevacizumab treatment. Brain Tumor Pathology. 2024
Akihiko Teshigawara, Tomoto Kyoichi, Yuzuru Hasegawa, Yuichi Murayama, Toshihide Tanaka. Comparative Volumetric Analyses Following Bevacizumab Therapy for a Patient With Concomitant Glioblastoma, Meningioma, and Dural Arteriovenous Fistula: A Case Report and Review of Literature. Cureus. 2024. 16. 9
Yohei Yamamoto, Kyoichi Tomoto, Akihiko Teshigawara, Takuya Ishii, Yuzuru Hasegawa, Yasuharu Akasaki, Yuichi Murayama, Toshihide Tanaka. Significance and priority of surgical resection as therapeutic strategy based on clinical characteristics of brain metastases from renal cell carcinoma. World Neurosurgery. 2024
TOSHIHIDE TANAKA, RYOTA TAMURA, JUN TAKEI, YUKINA MORIMOTO, AKIHIKO TESHIGAWARA, KYOICHI TOHMOTO, YUKI KURANARI, RYOTARO IMAI, YOHEI YAMAMOTO, YUZURU HASEGAWA, et al. ACT-1 A multicenter exploratory phase II study of neoadjuvant bevacizumab for newly diagnosed malignant glioma ~ The second report. Neuro-Oncology Advances. 2023. 5. v1-v2
COT-4 Comparative volumetric analyses following bevacizumab therapy for a patient with co-incidence of glioblastoma, meningioma, and dural arteriovenous fistula. 2023. 5. 5. v3-v3
ANGI-1 Regulation of alternative angiogenic factors in bevacizumab therapy for glioblastoma. 2023. 5. 5. v1-v2